Anaveon is a clinical-stage biopharmaceutical company, based in Switzerland, that develops biologics to modulate the function of cytokines and provide substantial therapeutic benefit to cancer patients. Our vision is to develop novel immune therapies benefiting patients suffering from a wide variety of diseases with immune pathology.

Aquinnah Pharmaceuticals is pursuing a novel hypothesis for the treatment of amyotrophic lateral sclerosis, Alzheimer’s disease and other neurodegenerative diseases by developing small molecule therapeutics that target persistent stress granules, a common pathology of neurodegeneration.

Arrakis Therapeutics is pioneering the discovery of small-molecule medicines that directly bind and modify the biological function of RNA to treat disease. This new class of medicines, RNA-targeted small molecules (rSMs), will focus on new disease intervention points identified in the human transcriptome as well as valuable targets that are not accessible with today’s medicines.

Artios Pharma is a leading DNA Damage Response (DDR) company focused on developing first-in-class treatments for cancer. The company is building a pipeline of next-generation DDR programmes to target hard to treat cancers.

Autifony is a UK-based biotechnology company, spun-out from GSK in 2011. The company is focused on the development of high value, novel medicines to treat serious diseases of the central nervous system.

Autobahn is a biotechnology company developing a pipeline of transformative small molecule therapies for the treatment of CNS disorders. The company’s lead program leverages a brain-targeting chemistry platform to target the unambiguous link between thyroid hormone and myelin biology. 

BioGraph 55 is focused on developing first-in-class antibody therapies that target B-cells in T-cell inflamed solid tumors. The company’s lead program is a novel bispecific antibody that depletes regulatory B-cells to remove local immunosuppression for clinically effective anti-tumor T-cell immunity. The bispecific antibody mediates killing through a unique mode of action and is highly selective. Early efficacy data in mice supports potential monotherapy efficacy and enhanced combination efficacy with immune checkpoint inhibitors. The company uses a reverse translational approach to identify potential cellular targets within the human solid tumor microenvironment followed by translational and mouse model studies to test and validate mechanisms.

Capstan is combining the power of in vivo cell therapy with the precision of genetic medicines to develop new treatment options for patients across oncology, fibrosis, inflammation-related diseases, and monogenic blood disorders. Our founders include inventors of the first clinically approved CAR-T and of lipid nanoparticles that are enabling mRNA medicines.

Cartography Biosciences is a company focused on identifying and developing tumor-specific therapeutics, leveraging a unique genomics and computational platform to find targets for immuno-oncology treatments. Their approach analyzes cancers through the lens of antigen expression, aiming to create more precise and effective immunotherapies.

Crossbow Therapeutics, Inc., is a biotechnology company determined to improve the lives of people with cancer by unlocking the therapeutic potential of T-cell receptor (TCR)-mimetic antibodies. The company’s T-BoltTM therapies are next-generation, easily assembled immunotherapies directed with high precision at previously unreachable cancer cell targets. Crossbow’s efficient and selective approach is designed to target the entire universe of cancer proteins, dramatically expanding the potential of antibody therapy to address many types of cancer.

Curve leverage its proprietary discovery platform to identify functional microcycles that modulate targets within their native intracellular environment. The company is developing a pipeline of new small molecule drugs, initially against high priority cancer targets.

DEM Bio is pursuing novel targets for solid tumors with a lead ADC program in preclinical studies. Targets were uncovered through a proprietary platform investigating myeloid checkpoint signaling via inter-cellular CRISPR screening using tumor cells, primary macrophages, and other innate immune effector cells.

Enara Bio is pioneering the discovery of ‘Dark Antigens’ – a new class of cancer-specific antigens from previously uncharted genomic dark matter. The company is building a pipeline of bispecific T-cell engagers against these novel antigens to improve treatment outcomes for broad populations of cancer patients.

Enlaza’s breakthrough War-LockTM technology enables generation of unique, highly-selective biologic drugs that are engineered to become warheads with the capacity to irreversibly lock to disease related targets. This is accomplished by leveraging their novel synthetic biology platform, coupled with proprietary amino acids, to precision-engineer biological medicines with improved efficacy and safety profiles.

EvolveImmune is harnessing their “Immunology First” approach to create first-in-category cancer medicines to transform the lives of patients by delivering superior, long-term outcomes compared to current anti-cancer therapies.  They leverage exceptional experience in immunology to swiftly advance our modular, precision biotherapeutics platform to exploit the full potential of the array of unprecedented and validated immuno-oncology targets which comprise our pipeline.

Flare Therapeutics is a biotechnology company changing the paradigm in drugging transcription factors with an initial focus in precision oncology. Flare’s proprietary engine is founded on the identification of novel druggable pockets, or ‘switch sites’, within transcription factor complexes that solve for where to drug and what to optimize for in tuning gene expression to discover small molecule precision medicines for cancer and other diseases.

FoRx Therapeutics is a recently incorporated privately held company aiming to develop first-in-class compounds for cancer treatment.  FoRx focuses on drugging key molecular targets involved in DNA replication stress, as a new approach towards the development of targeted anticancer drugs.

Greywolf Therapeutics is developing a first-of-its-kind approach to antigen modulation. The company’s innovative technology is centered on inhibiting the endoplasmic reticulum aminopeptidases (ERAP1 and ERAP2), which play a central role in the antigen presentation pathway. The company is leveraging its leadership in ERAP inhibition and antigen modulation to advance novel therapeutic approaches to address the source of immune dysfunction in oncology and autoimmunity.

ImCheck is driving innovation in two powerful new areas of immune system modulation: the butyrophilins superfamily of immunomodulatory molecules and gamma-delta T cells.  The company is developing next generation immunotherapeutics for patients with severe unmet medical needs with a primary focus on immuno-oncology, as well as exploring opportunities in autoimmune diseases.

Immunocodex is committed to designing novel tolerogenic mRNA vaccines which re-program immune cells, re-balance the immune system, and restore health in patients suffering from autoimmune diseases. Through the integration of key tolerance-inducing signals alongside disease-specific autoantigens, we engineer effective, targeted therapies for the treatment of disease, while limiting negative systemic side effects.

ImmunOs is leading the next generation of immunotherapies by fast-tracking new discoveries of novel human immunomodulatory proteins that have a role in the innate immune system for cancer treatment.

Indendia Therapeutics is inventing a novel class of anti-cancer therapies that reprogram the tumor microenvironment (TME). The interplay between cancer cells and their surrounding microenvironment is relevant in drug development as many cancers use the TME to build barriers that shield immune system attack. One approach, PRTH-101, breaks these barriers to overcome recalcitrant cancers.

Interius BioTherapeutics is an early-stage biotechnology company initially focused on treating hematologic malignancies by leveraging its platform to generate chimeric antigen receptor (CAR) T cells directly in vivo. Our unique therapeutic approach bypasses the need for ex vivo cell manipulations and the potentially toxic pre-conditioning chemotherapy required for standard CAR T-cell treatments.  The company is also developing applications beyond immuno-oncology that address diseases not amenable to current gene therapy modalities.

Kestrel Therapeutics leverages a foundation of unique science that employs a physical understanding of the drug-target interaction to build a lead program designed to potently address all RAS mutations in all tumor types.

Levicept is an asset-centric UK-based biotechnology company developing a novel, safe and efficacious biological therapy (LEVI-04 [p75NTR-Fc]) for the treatment of chronic pain.

Mediar is a preclinical stage biotechnology company developing therapeutics to halt, or even reverse, fibrosis.  The platform and pipeline are based on an emerging class of novel targets – fibrotic mediators – that play key roles in modulating myofibroblast biology and the development of fibrosis in chronically damaged organs.

MindImmune Therapeutics is a preclinical stage biotech company developing first-in-class drugs that target the immune system to treat CNS diseases. The company is at the forefront of biological advances linking the peripheral immune system to neuroinflammation.

MISSION is discovering and developing first-in-class therapeutics that inhibit disease associated  deubiquitinylase enzymes (DUBs) involved in serious diseases including mitochondrial diseases, neurodegeneration, inflammation, and cancer. The company has built a proprietary world-leading DUB platform that is generating a rich pipeline of potent and selective small molecule drugs.

Montis is a biotech company targeting perivascular macrophages, a subpopulation of macrophages that interact with the endothelial cells of the vasculature. The company’s mission is to exploit these cellular interactions with therapeutics to drive and sustain immune reactions against solid tumors.

Mozart is developing CD8 Treg modulators for the treatment of autoimmune and inflammatory diseases. These molecules selectively target the regulatory CD8 T cell network to counteract early events in the autoimmune inflammatory cascade. CD8 Treg Modulators are designed to restore the intrinsic functions of regulatory CD8 T cells to suppress and eliminate pathogenic immune cells, providing durable control of autoimmune and other inflammatory diseases.

National Resilience is a first-of-its-kind manufacturing and technology company dedicated to broadening access to complex medicines and protecting biopharmaceutical supply chains against disruption. Founded in 2020, the company is building a sustainable network of high-tech, end-to-end manufacturing solutions to ensure the medicines of today and tomorrow can be made quickly, safely, and at scale.

Nimbus harnesses the power of computational chemistry, structural biology and AI/ML to design breakthroughs for the treatment of substantial and underserved human diseases. The company’s focus is on metabolic diseases, cancer and immune-inflammatory disorders.

Normunity is developing oncology therapeutics targeting novel proteins that are recruited and repurposed by the tumor to create tumor-specific immunosuppression. In collaboration with the Lieping Chen lab at Yale, the company is generating novel biologics with its lead program, NRM-823, a T cell engager, being progressed for the treatment of multiple solid tumors.

Nucleome Therapeutics is decoding the disease-linked variants located in the dark matter of the human genome to discover first-in-class precision medicine. Nucleome’s platform combines pioneering 3D genome technology and machine learning to shed light on these variants by directly linking genes to diseases and mapping pathways with unprecedented precision for drug discovery for autoimmune diseases.

OTR Therapeutics is dedicated to transforming early-stage innovations into globally impactful therapies for critical diseases with high unmet medical needs. With a strategic focus on oncology, immunology and inflammation (I&I), and cardiovascular and metabolic (CVM) diseases, the company identifies and acquires distinctive assets from preclinical to early clinical stages, accelerating their development into differentiated, globally relevant treatments.

Palleon Pharmaceuticals is the leading biotechnology company focused on developing Glycoimmune Checkpoint inhibitors to treat cancer. The company’s proprietary platform integrates technologies and insights from Nobel laureate Carolyn Bertozzi to create a novel approach to treating cancer.

PrescriberPoint is transforming the way pharmaceutical companies interact with healthcare providers. The company is creating a digital marketplace based on a “pull” vs. “push” model where healthcare providers can access all the support they need from Pharmacos on their terms, industry-wide, in one place including access to product information, samples, rep and MSL support and patient assistance programs

ReCode is developing a proprietary non-viral Selective ORgan Targeting (SORT) LNP technology with lead indications in the rare pulmonary diseases of primary ciliary dyskinesia (PCD) and cystic fibrosis (CF). The SORT platform, which enables precise organ targeting of payloads via both systemic and local delivery, is compatible with a variety of payloads (mRNA, siRNA, DNA, small molecule), including mixed cargos such as RNA/protein complexes for gene editing.

RefleXion Medical is developing the first biologically guided radiation therapy system for treating solid tumors throughout the body. By uniquely leveraging Positron Emission Tomography (PET), RefleXion's patented technology uses signals that are continuously emitted from the tumor itself to guide the treatment beam.

Saama is an AI-driven Intelligent Clinical Cloud company, enabling the life sciences industry to conduct faster and safer clinical development and regulatory programs.  Their Life Science Analytics Cloud (LSAC) platform is used by many biopharmaceutical companies on thousands of studies.   LSAC’s rich applications facilitate an unprecedented, authoritative oversight of comprehensive clinical research data, enabling companies to file New Drug Applications (NDAs) more efficiently and bring drugs to market faster. 

Storm Therapeutics is a clinical stage biotechnology company focused on discovering and developing novel small molecule therapies targeting RNA modifying enzymes (RME) for oncology and other diseases.

Strata Oncology is a precision oncology company aiming to enable large-scale molecularly informed clinical cancer research.  The company has developed an end-to-end technology platform for sequencing tumors across a network of health systems and has used AI to build algorithms to determine the best course of therapy for patience on an individual level.

TRex Bio is a discovery-stage biotechnology company focused on making a meaningful difference in the lives of patients suffering from fatal or debilitating illnesses including autoimmune and inflammatory diseases. TRex aims to achieve this vision via functional manipulation of Tregs and other immune cells in a tissue-specific and disease-specific fashion.

Triana Biomedicines is developing molecular glue therapeutics initially tailored for targeted protein degradation applications. TRIANA is building its pipeline using a target-first, rational approach to molecular glue discovery, and aspires to develop products for a wide range of therapeutic applications.

Trimtech Therapeutics is developing selective small molecule degraders of toxic protein aggregates for treatment of neurodegenerative and peripheral diseases, while leaving functional monomers untouched. The company’s proprietary degrader technology leverages TRIM21 biology as pioneered by the company’s founders Dr Leo James and Dr Will McEwan from the University of Cambridge.

VitaDAO is a decentralized accelerator for drug development. The core mission is the acceleration of research and development in the longevity space.